AKI - Acute Kidney InjuryNCT06564376
Tailored MgSO4 Supplementation to Reduce Complications in Pediatric Heart Surgery
A study testing total magnesium and ionized magnesium in people with AKI - Acute Kidney Injury and Arrythmia, run by West Virginia University at 1 site in United States.
Trial summary
Lay Summary This study tests two ways of measuring blood magnesium after heart surgery. Children who need heart surgery may have heart and kidney problems after surgery. The right amount of magnesium in blood reduces this risk. This study will test the best way to measure magnesium. Read more about this study
- Who is it for?
- Ages 0 to 18 years
- Conditions the study is for
- AKI - Acute Kidney Injury, Arrythmia, Congenital Heart Disease
- What is being tested?
- total magnesium and ionized magnesium
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 96 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Aug 2026to Jun 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Children undergoing cardiac surgery utilizing cardiopulmonary bypass
Who cannot join
- Children undergoing cardiac surgery without cardiopulmonary bypass
- Children with Renal disease
- Children with pre-existing arrhythmia
- Children on anti-arrhythmia medication
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
West Virginia University
Morgantown, West Virginia, 26506
About this study
Official title: Individually Tailored MgSo4 Supplementation to Reduce Cardiac and Renal Complications in Pediatric Heart Surgery
Lay Summary
This study tests two ways of measuring blood magnesium after heart surgery. Children who need heart surgery may have heart and kidney problems after surgery. The right amount of magnesium in blood reduces this risk. This study will test the best way to measure magnesium. This will let doctors choose the right dose of MgSO4. MgSO4 is a magnesium supplement. Taking MgSO4 after heart surgery helps children. For each child, it is best to personalize MgSO4 dose. This is based on the amount of magnesium in blood. This study will test two ways of personalizing MgSO4 dose.
Read more
In the blood, there are two kinds of magnesium. Usually, blood magnesium tests measure both forms together. This does not say anything about active magnesium. This study will measure the two forms separately. Then, MgSO4 will be given based on either the active or whole magnesium. Measuring active magnesium is good. Active magnesium levels change faster than total. That means active magnesium tests may better protect children. Also, active magnesium has more of an impact on heart and kidney function. Focusing on the active form will help these organs stay healthy.
To test how well the MgSO4 is working, heart and kidneys will be examined. After surgery, certain harmful heart rhythms can occur. The types and number of harmful rhythms will be studied. Kidney problems can also happen after heart surgery. Kidney health will be studied. To help understand how active magnesium works, further tests will be done. These tests will look for evidence of poor health in the cells that make up the heart, kidney, and blood.
Read the detailed description
Hypothesis: Modulating patient Mg levels based on ionized Mg will have clinical and functional benefits over using total Mg, due to the increased sensitivity and specificity of the ionized form. The primary goal of this project is to experimentally test the benefit of maintaining ionized normomagnesemia after cardiac surgery in children with regard to renal function and arrhythmia incidence . A secondary goal is to develop a model for predicting AKI after cardiac surgery in children, using a machine learning approach to understand interrelationships between magnesium-dependent physiological processes (Figure 1B). Successful completion of this project will define the utility and positionality of ionized Mg as an actor in pediatric post-surgical AKI, and its synergy with established clinical and physiological outcomes.
Aim 1: Investigating use of ionized Mg for Mg repletion therapy
In this aim, patients will be randomized to one of two strategies for Mg repletion therapy, one utilizing ionized Mg, the other using total Mg. The effects of these two strategies on clinical and physiological outcomes will be measured, as will the durability of the different Mg repletion strategies in preventing or correcting hypomagnesemia. 96 participants will be enrolled in this study. Because arrhythmia risk and AKI risk are dramatically stratified by age, subjects will be age-matched into the following groups: 0-1 month, 2 months to 2 years, 3- 9 years, 9 years -18 years. Children will be randomly assigned to one of two Mg repletion strategies. Randomization will occur after consenting and reaffirmation that the child/family/guardian still continue to agree to participate in the study. For each age group there will be 24 sealed envelopes that identify which treatment strategy for magnesium repletion they will be assigned (Total or ionized). This envelope will be opened at SBAR prior to the induction of anesthesia. Magnesium levels will be drawn and sent as per standard protocol. All patients will have ionized magnesium levels obtained with every blood gas, but only those in the ionized group will the physicians see and treat the magnesium based upon that value. Patients with hypomagnesemia ( value less than or equal to 1.8 Mg/dl in the total Magnesium group will be given MgSO4 at a standard dose of 50 mg/kg over 1 hour beginning at the intraoperative stage and at every subsequent timepoint where an individual's lab values show hypomagnesemia (Table 1). Those patients in the ionized magnesium group will be dosed according to Table 1 beginning at the intraoperative stage and at every subsequent timepoint where an individual's lab values show hypomagnesemia (Table 1). Study participants will be blinded to treatment group. Researchers will not be blinded at the time of MgSO4 administration due to logistical pharmacy requirements. All data analysis including ECG analysis will be performed by blinded researchers. In one arm, Mg repletion will be titrated using ionized Mg as a measure, maintaining an ionized Mg level of 0.98-1.46 mg/dl. In the other, Mg repletion will be titrated using total Mg as a measure. Due to reagents used by WVU labs, the reference range for total Mg is 1.9-3.1 mg/dL; patients in the total Mg arm will be maintained in this range. To ensure proper electrolyte balance, Ca2+, K+, and Na+ will be maintained within appropriate ranges using standard methodology.
Mg level will be measured on all arterial blood gases. Mg will be measured at least: pre-incision, at the completion of the procedure, and twice a day for 48 hours after surgery. In order to assess differences in post-treatment Mg maintenance after cessation of therapy, ionized and total Mg levels will also be measured 4 hours after Mg supplementation.
Urinary NGAL and Creatinine will be measured pre-bypass, 2 hours after bypass and 24 hours after bypass to assess for renal injury.
Clinical outcomes to be measured include:
- Urine output, measured hourly for 48 hours after surgery.
- Blood lactate, measured at least daily (standard of care).
- Time to extubation.
- Occurrence of non-sinus cardiac rhythms, with special attention given to accelerated junctional rhythms.
Magnesium dosing Total Mg (mg/dL) Less than or equal to 1.8 MgSO4 dose 50 mg/kg Ionized Mg Observed Mg(Mg/dL) MgSO4 dose 1.3 10 mg/kg - 1 hr 1.2 20 mg/kg - 1 hr 1.0 30 mg/kg - 1 hr 0.9 40 mg/kg - 1 hr 0.8 50 mg/kg - 1hr
- Being tested
- total magnesium, ionized magnesium
- Keywords
- Acute Kidney Injury, Arrhythmias, Congenital heart surgery, Cardiopulmonary bypass
- Medical subject headings
- Acute Kidney Injury, Arrhythmias, Cardiac, Heart Defects, Congenital
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
total magnesiumDiagnostic test
Treatment based on total Magnesium
ionized magnesiumDevice
Treatment based on ionized magnesium
| Study group | Role | What they receive |
|---|---|---|
| Total magnesium | Other | Magnesium dosing based on total Mg blood level Receives: Diagnostic Test: total magnesium |
| ionized Magnesium | Active comparator | Magnesium dosing based upon ionized Mg level Receives: Device: ionized magnesium |
What is being measured
The primary outcome is the main question the study is designed to answer.
Duration from reanimation to sinus rhythm
Measured: 48 hours after reanimation
Time in non-sinus rhythms: within 24h of removing aortic cross-clamp
Measured: first 24 hours after reanimation
Time in non-sinus rhythms: 24-48h after removing aortic cross-clamp
Measured: 24-48 hours after reanimation
Presence of any arrhythmia
Defined as any non-sinus rhythm
Measured: 48 hours after reanimation
Urine NGAL concentration
Sensitive marker of acute kidney injury
Measured: 48 hours after reanimation
Urine Creatinine concentration
The combination of NGAL/Creatine increases sensitivity marker of acute kidney injury
Measured: 48 hours after reanimation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2024
- Study start1 Aug 2026 (estimated)
- Primary completionDec 2028 (estimated)
- Study completionJun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AKI - Acute Kidney InjuryStudies of the same condition, open and under way.
- More trials run by West Virginia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 96 participants (estimated)
Sponsor and investigators
- Lead sponsor
- West Virginia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, David Rosen, MD, West Virginia University
- Investigators
- David A Rosen, MD, Principal investigator, West Virginia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06564376
- Sponsor's protocol ID
- 2310861427
- Status last verified
- Jun 2026
- First submitted
- 19 Aug 2024
- Last updated
- 16 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 16 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Individually Tailored MgSo4 Supplementation to Reduce Cardiac and Renal Complications in Pediatric Heart Surgery
- ClinicalTrials.gov ID
- NCT06564376
- Acronym / sponsor ID
- 2310861427
- Keywords
- Acute Kidney Injury, Arrhythmias, Congenital heart surgery, Cardiopulmonary bypass
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 96 participants (estimated)
- Lead sponsor
- West Virginia UniversityUniversity, hospital or other
- Study start
- 1 Aug 2026 (estimated)
- Primary completion
- Dec 2028 (estimated)
- Study completion
- Jun 2029 (estimated)
- First posted
- 21 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lay Summary
This study tests two ways of measuring blood magnesium after heart surgery. Children who need heart surgery may have heart and kidney problems after surgery. The right amount of magnesium in blood reduces this risk. This study will test the best way to measure magnesium. This will let doctors choose the right dose of MgSO4. MgSO4 is a magnesium supplement. Taking MgSO4 after heart surgery helps children. For each child, it is best to personalize MgSO4 dose. This is based on the amount of magnesium in blood. This study will test two ways of personalizing MgSO4 dose.
In the blood, there are two kinds of magnesium. Usually, blood magnesium tests measure both forms together. This does not say anything about active magnesium. This study will measure the two forms separately. Then, MgSO4 will be given based on either the active or whole magnesium. Measuring active magnesium is good. Active magnesium levels change faster than total. That means active magnesium tests may better protect children. Also, active magnesium has more of an impact on heart and kidney function. Focusing on the active form will help these organs stay healthy.
To test how well the MgSO4 is working, heart and kidneys will be examined. After surgery, certain harmful heart rhythms can occur. The types and number of harmful rhythms will be studied. Kidney problems can also happen after heart surgery. Kidney health will be studied. To help understand how active magnesium works, further tests will be done. These tests will look for evidence of poor health in the cells that make up the heart, kidney, and blood.
Detailed description
Hypothesis: Modulating patient Mg levels based on ionized Mg will have clinical and functional benefits over using total Mg, due to the increased sensitivity and specificity of the ionized form. The primary goal of this project is to experimentally test the benefit of maintaining ionized normomagnesemia after cardiac surgery in children with regard to renal function and arrhythmia incidence . A secondary goal is to develop a model for predicting AKI after cardiac surgery in children, using a machine learning approach to understand interrelationships between magnesium-dependent physiological processes (Figure 1B). Successful completion of this project will define the utility and positionality of ionized Mg as an actor in pediatric post-surgical AKI, and its synergy with established clinical and physiological outcomes.
Aim 1: Investigating use of ionized Mg for Mg repletion therapy
In this aim, patients will be randomized to one of two strategies for Mg repletion therapy, one utilizing ionized Mg, the other using total Mg. The effects of these two strategies on clinical and physiological outcomes will be measured, as will the durability of the different Mg repletion strategies in preventing or correcting hypomagnesemia. 96 participants will be enrolled in this study. Because arrhythmia risk and AKI risk are dramatically stratified by age, subjects will be age-matched into the following groups: 0-1 month, 2 months to 2 years, 3- 9 years, 9 years -18 years. Children will be randomly assigned to one of two Mg repletion strategies. Randomization will occur after consenting and reaffirmation that the child/family/guardian still continue to agree to participate in the study. For each age group there will be 24 sealed envelopes that identify which treatment strategy for magnesium repletion they will be assigned (Total or ionized). This envelope will be opened at SBAR prior to the induction of anesthesia. Magnesium levels will be drawn and sent as per standard protocol. All patients will have ionized magnesium levels obtained with every blood gas, but only those in the ionized group will the physicians see and treat the magnesium based upon that value. Patients with hypomagnesemia ( value less than or equal to 1.8 Mg/dl in the total Magnesium group will be given MgSO4 at a standard dose of 50 mg/kg over 1 hour beginning at the intraoperative stage and at every subsequent timepoint where an individual's lab values show hypomagnesemia (Table 1). Those patients in the ionized magnesium group will be dosed according to Table 1 beginning at the intraoperative stage and at every subsequent timepoint where an individual's lab values show hypomagnesemia (Table 1). Study participants will be blinded to treatment group. Researchers will not be blinded at the time of MgSO4 administration due to logistical pharmacy requirements. All data analysis including ECG analysis will be performed by blinded researchers. In one arm, Mg repletion will be titrated using ionized Mg as a measure, maintaining an ionized Mg level of 0.98-1.46 mg/dl. In the other, Mg repletion will be titrated using total Mg as a measure. Due to reagents used by WVU labs, the reference range for total Mg is 1.9-3.1 mg/dL; patients in the total Mg arm will be maintained in this range. To ensure proper electrolyte balance, Ca2+, K+, and Na+ will be maintained within appropriate ranges using standard methodology.
Mg level will be measured on all arterial blood gases. Mg will be measured at least: pre-incision, at the completion of the procedure, and twice a day for 48 hours after surgery. In order to assess differences in post-treatment Mg maintenance after cessation of therapy, ionized and total Mg levels will also be measured 4 hours after Mg supplementation.
Urinary NGAL and Creatinine will be measured pre-bypass, 2 hours after bypass and 24 hours after bypass to assess for renal injury.
Clinical outcomes to be measured include:
- Urine output, measured hourly for 48 hours after surgery.
- Blood lactate, measured at least daily (standard of care).
- Time to extubation.
- Occurrence of non-sinus cardiac rhythms, with special attention given to accelerated junctional rhythms.
Magnesium dosing Total Mg (mg/dL) Less than or equal to 1.8 MgSO4 dose 50 mg/kg Ionized Mg Observed Mg(Mg/dL) MgSO4 dose 1.3 10 mg/kg - 1 hr 1.2 20 mg/kg - 1 hr 1.0 30 mg/kg - 1 hr 0.9 40 mg/kg - 1 hr 0.8 50 mg/kg - 1hr
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Total magnesium | Other | Diagnostic Test: total magnesiumMagnesium dosing based on total Mg blood level |
| ionized Magnesium | Active comparator | Device: ionized magnesiumMagnesium dosing based upon ionized Mg level |
Who may qualify
- Ages
- 0 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- Children undergoing cardiac surgery utilizing cardiopulmonary bypass
Key exclusion criteria (4 listed)
- Children undergoing cardiac surgery without cardiopulmonary bypass
- Children with Renal disease
- Children with pre-existing arrhythmia
- Children on anti-arrhythmia medication
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| total magnesiumTreatment based on total Magnesium | Diagnostic test | Total magnesium |
| ionized magnesiumTreatment based on ionized magnesium | Device | ionized Magnesium |
Primary outcome
Duration from reanimation to sinus rhythm
Time frame: 48 hours after reanimation
Time in non-sinus rhythms: within 24h of removing aortic cross-clamp
Time frame: first 24 hours after reanimation
Time in non-sinus rhythms: 24-48h after removing aortic cross-clamp
Time frame: 24-48 hours after reanimation
Presence of any arrhythmia
Time frame: 48 hours after reanimation
Defined as any non-sinus rhythm
Urine NGAL concentration
Time frame: 48 hours after reanimation
Sensitive marker of acute kidney injury
Urine Creatinine concentration
Time frame: 48 hours after reanimation
The combination of NGAL/Creatine increases sensitivity marker of acute kidney injury
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jun 2026.
Related trials for AKI - Acute Kidney Injury
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery
Renal Injury, Acute Kidney Injury
Recruiting
Acute Kidney Injury and Ultra-endurance Running
AKI (Acute Kidney Injury) Due to Trauma
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
Not yet recruiting
Neuromuscular Electrical Stimulation to Improve the Muscle Health of Individuals With Acute Kidney Injury
Acute Kidney Injury, Acute Kidney Injury KDIGO 2
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
David A Rosen, MD principal investigator
West Virginia University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing total magnesium and ionized magnesium in people with AKI - Acute Kidney Injury and Arrythmia, run by West Virginia University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact David A Rosen, MD (3045984000 ext. 4122, rosend@wvumedicine.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Duration from reanimation to sinus rhythm (time frame: 48 hours after reanimation). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jun 2026.